Skip to main content

Advertisement

Table 2 Morbidity characteristics of participants residing in Edmonton, Alberta during the April 2008 to March 2009 fiscal year

From: Methods for identifying 30 chronic conditions: application to administrative data

  Prevalence, %
Characteristic Final algorithm Using hospitalizations, claims, and ACCS Using only hospitalizations and claims Using only hospitalizations and ACCS Using only hospitalizations
Number of morbidities
One 23.3 24.0 23.9 12.0 6.9
Two 11.5 12.1 11.9 4.9 3.7
Three 5.6 6.0 5.8 2.5 2.1
Four 2.8 3.1 2.9 1.4 1.1
Five or more 3.4 3.7 3.4 1.8 1.4
Morbidities
Alcohol misuse 2.4 2.8 2.4 2.4 1.8a
Asthma 2.3 6.9 6.8 2.3 b 2.0b
Atrial fibrillation 2.4 2.5 2.4 1.9 1.6a
Cancer, lymphoma 0.2 0.2 0.2 0.1a 0.1a
Cancer, metastatic 0.6 0.6 0.6 0.5 0.5
Cancer, non-metastatic 2.2 2.2 2.2 1.1b 1.0b
Chronic heart failure 2.5 2.6 2.5 1.6a 1.4a
Chronic kidney disease1 20.8 3.8 (20.9) 3.6 (20.8) 2.9 (20.4) 2.2 (20.1)a
Chronic pain 6.5 6.5 5.2 1.4b 0.1b
Chronic pulmonary disease 7.0 7.2 7.0 2.7b 2.3b
Chronic viral hepatitis B 0.1 0.1 0.1 0.1b <0.1b
Cirrhosis 0.2 0.2 0.1 0.1 0.1a
Dementia 1.6 1.6 1.6 1.1a 0.9a
Depression 8.7 8.9 8.7 1.7b 1.0b
Diabetes 8.8 8.9 8.8 5.6a 3.1b
Epilepsy 1.4 1.4 1.2 0.7b 0.1b
Hypertension 22.8 23.0 22.8 8.8b 7.8b
Hypothyroidism 7.6 7.6 7.6 2.3b 2.2b
Inflammatory bowel disease 1.0 1.1 1.0 0.7a 0.2b
Irritable bowel syndrome 1.9 2.0 1.9 0.6b 0.4b
Multiple sclerosis 0.7 0.8 0.7 0.4a 0.1b
Myocardial infarction 1.7 - - - 1.7
Parkinson’s disease 0.5 0.5 0.5 0.3b 0.2b
Peptic ulcer disease 0.2 0.2 0.2 0.1a 0.1b
Peripheral vascular disease 0.7 0.7 0.6 0.3b 0.2b
Psoriasis 0.9 1.0 0.9 0.2b 0.1b
Rheumatoid arthritis 1.5 1.6 1.5 0.8a 0.5b
Schizophrenia 1.5 1.5 1.5 0.7b 0.6b
Severe constipation 0.6 0.7 0.6 0.4a 0.3b
Stroke or transient ischemic attack 4.2 4.2 3.8 2.4a 0.9b
  1. aIndicate morbidities where removing a sources or sources resulted in prevalence reduced between 25 to 50% compared to estimates using all three sources. bDemonstrates morbidities where prevalence was reduced >50% compared to all three sources.
  2. The prevalence values in the first column and the bold prevalence values in the remaining columns are estimates from the final algorithms given in Table 1. The bolded prevalence values indicate which administrative datasets were used in the final algorithms.
  3. 1Values in brackets include laboratory data (estimated glomerular filtration rate and albuminuria) as gold standard measures of kidney function